September 30, 2009
Asahi Kasei Corporation

Launch of Reveal® DX Insertable Cardiac Monitor
Asahi Kasei Corp. (Head Office: Chiyoda-ku, Tokyo; President: Shiro Hiruta) will begin sales of the Reveal® DX insertable cardiac monitor in Japan on October 1, 2009, the date the device will be applicable for coverage by Japan's National Health Insurance.

Reveal® DX, for which Asahi Kasei acquired the exclusive rights for domestic sale from Medtronic Japan Co., Ltd. (Head Office: Minato-ku, Tokyo; President: Takashi Shimada) in July 2008, is the first insertable cardiac monitor available in Japan. It is placed beneath the skin of a patient's chest to provide the physician with a high resolution electrocardiogram of the patient's unexplained syncope (fainting spell) to determine if the syncope is caused by an arrhythmia (irregular heartbeat).

Preparations for sales of the Reveal® DX are being handled by Asahi Kasei's Advanced Medical Device Center, a new business group at the company. With the initiation of insurance coverage, the device will mainly be sold to medical institutions which specialize in unexplained syncope or arrhythmia.
About Reveal® DX
Product name:   Medtronic Reveal® DX
Generic name:   Insertable cardiac monitor
Purpose of use:   Indicated for patients who have had unexplained syncope. A device to record and store electrocardiograms for diagnosis, to be implanted under the skin of the upper chest of patients for whom diagnosis of syncope could not be made using tests deemed necessary by a physician.
Marketing Authorization Holder:   Medtronic Japan Co., Ltd.
Start of insurance coverage:   October 1, 2009
Sales launch:   October 1, 2009
Price:   ¥422,000 per device
About Unexplained Syncope
  In Japan, it is estimated that approximately 200,000 people per year are taken to the hospital after syncope, but normal test methods are unable to determine the cause of the syncope in 20-30% of these cases. Due to the possible links of unexplained syncope with possible life-threatening serious arrhythmias, physicians require precise methods for differential diagnosis.
About Medtronic Japan
  Medtronic Japan was founded in 1975 and has spent more than 30 years alleviating pain and restoring life for Japanese patients suffering from chronic diseases. Medtronic therapies cover a wide range of afflictions, from cardiac diseases to Parkinson's disease, diabetes, spinal disorders, cerebral disorders, chronic pain and other chronic conditions.
Company website:
Reveal® is a registered trademark of Medtronic, Inc.


Adobe Readeris required to view these PDF files.

page top